Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate versus delayed low-dose testosterone for transgender health
ACTRN12624001337561Phase 4Not yet recruiting
- Sponsor
- University of Melbourne
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of testosterone in gender dysphoria (GD) and major depressive disorder (MDD), sponsored by University of Melbourne. Primary endpoints: Symptoms of gender dysphoria, Gender euphoria and 1 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
testosterone
03
Conditions
gender dysphoria (GD)major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12624001337561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001337561.